Brandenburger A - Search Results

1

Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus.

Russell SJ, Brandenburger A, Flemming CL, Collins MK, Rommelaere J. Russell SJ, et al. Among authors: brandenburger a. J Virol. 1992 May;66(5):2821-8. doi: 10.1128/JVI.66.5.2821-2828.1992. J Virol. 1992. PMID: 1560527 Free PMC article.

2

NS-1 and NS-2 proteins may act synergistically in the cytopathogenicity of parvovirus MVMp.

Brandenburger A, Legendre D, Avalosse B, Rommelaere J. Brandenburger A, et al. Virology. 1990 Feb;174(2):576-84. doi: 10.1016/0042-6822(90)90110-d. Virology. 1990. PMID: 2137660

3

A novel packaging system for the generation of helper-free oncolytic MVM vector stocks.

Brandenburger A, Russell S. Brandenburger A, et al. Gene Ther. 1996 Oct;3(10):927-31. Gene Ther. 1996. PMID: 8908507

4

Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins.

Caillet-Fauquet P, Perros M, Brandenburger A, Spegelaere P, Rommelaere J. Caillet-Fauquet P, et al. Among authors: brandenburger a. EMBO J. 1990 Sep;9(9):2989-95. doi: 10.1002/j.1460-2075.1990.tb07491.x. EMBO J. 1990. PMID: 2167840 Free PMC article.

5

Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1.

Van Pachterbeke C, Tuynder M, Brandenburger A, Leclercq G, Borras M, Rommelaere J. Van Pachterbeke C, et al. Among authors: brandenburger a. Eur J Cancer. 1997 Sep;33(10):1648-53. doi: 10.1016/s0959-8049(97)00153-6. Eur J Cancer. 1997. PMID: 9389929

6

Cloning and sequencing of defective particles derived from the autonomous parvovirus minute virus of mice for the construction of vectors with minimal cis-acting sequences.

Clément N, Avalosse B, El Bakkouri K, Velu T, Brandenburger A. Clément N, et al. Among authors: brandenburger a. J Virol. 2001 Feb;75(3):1284-93. doi: 10.1128/JVI.75.3.1284-1293.2001. J Virol. 2001. PMID: 11152501 Free PMC article.

7

Hypoxic-response elements in the oncolytic parvovirus Minute virus of mice do not allow for increased vector production at low oxygen concentration.

Servais C, Caillet-Fauquet P, Draps ML, Velu T, de Launoit Y, Brandenburger A. Servais C, et al. Among authors: brandenburger a. J Gen Virol. 2006 May;87(Pt 5):1197-1201. doi: 10.1099/vir.0.81754-0. J Gen Virol. 2006. PMID: 16603521

8

Influence of sequence and size of DNA on packaging efficiency of parvovirus MVM-based vectors.

Brandenburger A, Coessens E, El Bakkouri K, Velu T. Brandenburger A, et al. Hum Gene Ther. 1999 May 1;10(7):1229-38. doi: 10.1089/10430349950018210. Hum Gene Ther. 1999. PMID: 10340554

9

In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA.

El Bakkouri K, Servais C, Clément N, Cheong SC, Franssen JD, Velu T, Brandenburger A. El Bakkouri K, et al. Among authors: brandenburger a. J Gene Med. 2005 Feb;7(2):189-97. doi: 10.1002/jgm.653. J Gene Med. 2005. PMID: 15515141

10

A novel method for the titration of recombinant virus stocks by ELISPOT assay.

Cheong SC, Clément N, Velu T, Brandenburger A. Cheong SC, et al. Among authors: brandenburger a. J Virol Methods. 2003 May;109(2):119-24. doi: 10.1016/s0166-0934(03)00061-2. J Virol Methods. 2003. PMID: 12711053

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters